Condition: Immune Thrombocytopenia (ITP) · Sponsor: Peking University People's Hospital
A multicenter, open-label, randomized study to report the efficacy and safety of teriflunomide plus high-dose dexamethasone compared to high-dose dexamethasone monotherapy for the first-line treatment of adults with newly diagnosed primary immune thrombocytopenia (ITP).
This description comes directly from the study's public registry record.
Xiao-Hui Zhang, MD · +8613522338836 · zhangxh@bjmu.edu.cn
Li-Ping Yang, MD · +8618519172033 · lpyang@bjmu.edu.cn
Always discuss trial participation with your own doctor first.
| Peking University First Hospital | Beijing, Beijing Municipality, China | Recruiting |
| Peking University Insititute of Hematology, Peking University People's Hospital | Beijing, Beijing Municipality, China | Recruiting |
| Peking University Third Hospital | Beijing, Beijing Municipality, China | Recruiting |
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT07065968